InterCure Ltd. (NASDAQ:INCR) Short Interest Up 72.6% in June

Posted by ABMN Staff on Jul 4th, 2026

InterCure Ltd. (NASDAQ:INCR – Get Free Report) was the recipient of a significant increase in short interest in June. As of June 15th, there was short interest totaling 47,234 shares, an increase of 72.6% from the May 31st total of 27,374 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 74,696 shares, the short-interest ratio is currently 0.6 days.

InterCure Price Performance

INCR opened at $1.09 on Friday. The business’s fifty day moving average is $0.94 and its two-hundred day moving average is $0.92. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.97 and a current ratio of 1.48. The company has a market cap of $59.60 million, a price-to-earnings ratio of 36.33 and a beta of 1.39. InterCure has a one year low of $0.68 and a one year high of $1.77.

InterCure (NASDAQ:INCR – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.10) earnings per share for the quarter. The firm had revenue of $23.15 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of InterCure in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Read Our Latest Stock Report on InterCure

InterCure Company Profile

(Get Free Report)

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.